START FREE TRIAL
Home Healthcare AXOGEN

AXOGEN

$19.00

SKU: AXGN Category:

Description

Axogen’s $290 Million Revenue Outlook: Can Nerve Repair Demand Sustain 29% Growth?

 

Axogen, Inc. reported third quarter 2026 results marked by continued revenue growth and expanding market penetration across its core nerve repair markets. Total revenue reached $75.8 million, up 26.2% year-over-year, driven by strength in all product lines and geographies. The breast reconstruction segment notably grew over 60% in the quarter, supported by increasing surgeon adoption and new account development, with approximately 485 active breast reconstruction accounts and 590 surgeons trained year-to-date. Extremities and oromaxillofacial/head and neck markets also demonstrated double-digit growth, fueled by expanded application of the company’s nerve repair algorithm. Adjusted EBITDA improved to $13.4 million with margin expansion of 2.3 percentage points compared to the prior year. GAAP net income was $2.3 million, reflecting modest profitability. Gross margin declined slightly year-over-year to 74.8%, influenced by higher product costs and inventory cost adjustments related to demand for long-length Avance grafts, particularly in breast reconstruction.